Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Downgrades Home Point Capital to Underweight

JP Morgan analyst Richard Shane downgrades Home Point Capital (NASDAQ:HMPT) from Overweight to Underweight.
byBenzinga Newsdesk
January 19, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

JP Morgan analyst Richard Shane downgrades Home Point Capital (NASDAQ:HMPT) from Overweight to Underweight.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AVROBIO Announced Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy Annual Meeting; Said Data Support Plans to Initiate Clinical Trial in 2023

By Charles Gross
Today, 10:21 PM
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease.

AVRO